Showing results (511-520 of 599) with videos related to

Sort By:
Pageof 60
RMD Open|August 13, 2025
Assessing the MUC5B promoter variant in a large cohort of systemic sclerosis-associated interstitial lung diseaseCarlos Rosa-Baez, Carlos Rangel-Pelaez, Inmaculada Rodriguez-Martin, et al.
Diagnostics (Basel, Switzerland)|February 10, 2024
The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the European Scleroderma Trial and Research DatabaseGemma Lepri, Cosimo Bruni, Lorenzo Tofani, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Annals of the Rheumatic Diseases|January 28, 2025
EULAR recommendations for the treatment of systemic sclerosis: 2023 updateFrancesco Del Galdo, Alain Lescoat, Philip G Conaghan, et al.
Rheumatology (Oxford, England)|May 15, 2024
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre studyGiacomo De Luca, Enrico De Lorenzis, Corrado Campochiaro, et al.
The Journal of Rheumatology|March 17, 2012
Independent replication and meta analysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosisBaptiste Coustet, Matthieu Bouaziz, Philippe Dieudé, et al.
Arthritis and Rheumatism|August 29, 2013
A regulatory variant in CCR6 is associated with susceptibility to antitopoisomerase-positive systemic sclerosisEugénie Koumakis, Matthieu Bouaziz, Philippe Dieudé, et al.
The Lancet. Rheumatology|January 22, 2024
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trialOliver Distler, Yannick Allanore, Christopher P Denton, et al.
Annals of the Rheumatic Diseases|October 11, 2024
EULAR recommendations for the treatment of systemic sclerosis: 2023 updateFrancesco Del Galdo, Alain Lescoat, Philip G Conaghan, et al.
Microorganisms|July 8, 2020
Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern ItalyLorenzo Cavagna, Elena Seminari, Giovanni Zanframundo, et al.
Pageof 60